The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

硼替佐米 蛋白酶体 蛋白酶体抑制剂 细胞培养 癌症研究 生物 药理学 多发性骨髓瘤 医学 化学 分子生物学 免疫学 生物化学 遗传学
作者
N. Franke,Johan van Meerloo,Linda M. Slot,Xiaoming Li,Tabitha E. Wood,Katarina Vojtekova,Sue Ellen Verbrugge,Gertjan J.L. Kaspers,Robert A. Batey,Aaron D. Schimmer,Gerrit Jansen,Jacqueline Cloos
出处
期刊:Blood [Elsevier BV]
卷期号:114 (22): 940-940 被引量:1
标识
DOI:10.1182/blood.v114.22.940.940
摘要

Abstract Abstract 940 The proteasome inhibitor Bortezomib (BTZ, Velcade®) specifically inhibits the catalytic beta 5 subunit of the proteasome, thereby interfering in the degradation of proteins involved in cell-cycling, NF-kB activation, apoptosis induction and micro-environmental interactions. The introduction of BTZ has shown promising results in the treatment of Multiple Myeloma (MM), Non-Hodgkin lymphoma and leukemia. Despite these encouraging results, clinical trials in MM also revealed that a significant proportion of patients acquired resistance to BTZ mono-therapy. Previously we reported the development of three different BTZ-resistant cell line models, including the AML THP-1 cell-line (Oerlemans & Franke et al, Blood 2008), the T-ALL CCRF-CEM-C7 cell-line and the MM RPMI-8226 cell line (Franke et al, ASH 2008) after chronic exposure to stepwise increasing concentrations of BTZ. The aim of our current study was to further elucidate the molecular basis of BTZ resistance in these cell lines and investigate whether the resistant phenotype could be overcome by the second generation proteasome inhibitor 5-amino-8-hydroxyquinole (5AHQ), acting as a non-competitive inhibitor of the non-catalytic alpha-7 subunit of the proteasome (Li et al. ASH 2008). When added to intact cells, cell extracts, or isolated rabbit reticulocyte proteasomes (gift of A Navon, Weizmann Institute of Science, Israel), 5AHQ inhibited the chymotrypsin-like enzymatic activity of the proteasome with IC50's of 6.9 ± 0.05 uM, 4.2 ± 0.6 uM, and 2.1 ± 0.18 μM, respectively. Cells were initially selected for growth at 7 nM BTZ to acquire low levels of BTZ resistance (2-3 fold higher IC50 concentrations) and subsequently challenged to higher concentrations of BTZ (up to 500 nM) to provoke higher resistance levels. Sequencing of the PSMB5 gene, encoding for the beta 5 proteasome subunit, revealed a series of mutations in individual BTZ-resistant subclones. An overview of the mutation site in the PSMB5 gene, the amino acid position at which substitutions take place at the beta 5 subunit protein level, and the functional implication of each mutation are depicted in the table below. Subsequently, we determined whether THP-1, CEM and 8226 cells with low and high levels of BTZ resistance would be sensitive towards the new proteasome inhibitor 5AHQ. Strikingly, all BTZ-resistant selectants retained full sensitivity towards 5AHQ (IC50: 4-7 μM, measured in a 4-day MTT cytotoxicity assay) as compared to parental cells. Together, these data indicate that in vitro selection of low and high levels of BTZ resistance in 3 hematological cell lines is accompanied by the introduction of multiple mutations of amino acids, all of which have key positions in BTZ binding within the active site of the proteasome beta 5 subunit. Notably, Ala49 mutations were independently observed in all 3 cell lines selected for BTZ concentrations > 100 nM. Knowledge of specific mutations in the PSMB5 gene that can confer BTZ resistance allows purposive screening for these types of mutations in clinical samples of BTZ refractory patients. In this respect, the notion that 5AHQ can bypass BTZ resistance related to single or multiple mutations in the PSMB5 gene, supports further preclinical development and clinical application of this drug. This study is supported by VUmc - Stichting Translational Research (STR) and The Netherlands Organization for Health Research and Development (ZonMw), The Leukemia and Lymphoma Society and the Ontario Institute for Cancer Research through funding from the Ministry of Research and Innovation, Province of Ontario. Disclosures: No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
NexusExplorer应助fiell采纳,获得10
刚刚
勤劳的乐安完成签到,获得积分10
1秒前
kitty发布了新的文献求助20
2秒前
kiltorh完成签到,获得积分10
2秒前
Orange应助平常的路人采纳,获得10
2秒前
3秒前
风犬少年完成签到,获得积分10
3秒前
3秒前
懒懒洋洋洋完成签到 ,获得积分10
3秒前
4秒前
詹密完成签到,获得积分10
4秒前
积极含羞草完成签到,获得积分10
5秒前
故事的小红花完成签到,获得积分10
5秒前
QWDSA完成签到,获得积分10
6秒前
龙华之士发布了新的文献求助10
7秒前
7秒前
北冥有鱼完成签到,获得积分10
9秒前
Yddear发布了新的文献求助10
9秒前
manfullmoon完成签到,获得积分10
9秒前
鲨鱼也蛀牙完成签到,获得积分10
9秒前
Dragon完成签到 ,获得积分10
9秒前
9秒前
李健应助小王采纳,获得10
10秒前
云轩完成签到,获得积分10
12秒前
顾矜应助王铂然采纳,获得10
13秒前
13秒前
13秒前
岩下松风完成签到,获得积分10
14秒前
zzzyyyuuu完成签到 ,获得积分10
14秒前
默默白桃完成签到 ,获得积分10
14秒前
hbsand完成签到,获得积分10
16秒前
cao完成签到 ,获得积分10
17秒前
Jasper应助fanicky采纳,获得10
17秒前
Yddear完成签到,获得积分10
17秒前
18秒前
21秒前
彩色的芷烟完成签到,获得积分10
21秒前
无心的平蝶完成签到,获得积分10
21秒前
22秒前
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038446
求助须知:如何正确求助?哪些是违规求助? 3576149
关于积分的说明 11374627
捐赠科研通 3305875
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892680
科研通“疑难数据库(出版商)”最低求助积分说明 815048